Tauklarify (florquinitau F 18 injection) is a brain PET tracer that binds tau tangles, the twisted tau proteins linked to Alzheimer's. In August 2026 it became the second FDA-approved tau PET tracer, while two newly cleared blood tests expanded early triage, especially for younger-onset families. For those families, the practical change is sequence: a blood test can flag Alzheimer's biology earlier, starting at age 40, while tau PET helps confirm tau burden and stage disease for treatment decisions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Tauklarify add to PET imaging?
- What changed in Alzheimer's blood tests?
- How do blood tests and tau PET work together?
- What should younger-onset families do next?
What does Tauklarify add to PET imaging?
Tauklarify is approved for brain PET in cognitively impaired adults evaluated for Alzheimer's to identify tau tangle pathology. According to Lantheus, the FDA approval came on Aug. 14, 2026 the FDA approval notice. It joins flortaucipir (Tauvid) as a second tau PET option. According to the Society of Nuclear Medicine and Molecular Imaging, it complements amyloid PET rather than replacing it the Society overview.
Amyloid PET shows plaques. Tau PET shows tangles. The tracer has clear limits. According to Lantheus, safety and effectiveness are not established for non-Alzheimer tauopathies. Accuracy was tested mainly in amyloid-negative people without impairment versus amyloid-positive people with impairment.
What changed in Alzheimer's blood tests?
The U.S. now has four FDA-cleared Alzheimer's blood tests. According to Medical News Today, the two August 2026 clearances joined Lumipulse pTau217/amyloid ratio from May 2025 and Elecsys pTau181 from Oct. 2025 the test-roundup report. One clearance lowers the age floor. According to C2N Diagnostics, PrecivityAD2 was cleared on Aug.
20, 2026 for adults age 40 and older with cognitive symptoms the C2N announcement. It uses high-resolution mass spectrometry. The other clearance simplifies the marker. According to Roche, the Elecsys Phospho-Tau (217P) Plasma test was cleared on Aug. 24, 2026 for people 55 and older with signs or complaints of cognitive decline to aid amyloid-pathology assessment. It measures a single biomarker, pTau217, in plasma.
How do blood tests and tau PET work together?
Blood pTau217 can rise years before amyloid PET turns abnormal. That makes it useful for triage. Tau PET then helps confirm tau burden and stage disease. According to the 2026 study evidence reported by Medical News Today, that triage-then-confirm sequence is the practical shift for younger-onset families.
A positive blood result does not by itself diagnose Alzheimer's. It points to the need for specialty follow-up and often confirmatory imaging. Testing still belongs after clinical evaluation in specialty care for people with objective impairment. According to the Alzheimer's Association 2025 guideline, tests used for triage or as a PET substitute should meet about 90% sensitivity and 75-90% specificity.
What should younger-onset families do next?
Start with symptoms, not with shopping for a test. Document examples of memory, language, planning, or behavior change with dates.
Bring a family member who sees daily function. Ask the specialty clinic about fit: Bring prior cognitive test results, medication lists, and imaging history to that visit. Ask how the clinic will explain a positive blood triage result before PET confirmation.
- age and symptom criteria for PrecivityAD2 at 40-plus or Elecsys pTau217 at 55-plus
- whether a blood result would change referral, imaging, or treatment planning
- when tau PET is needed to assess tau burden and stage
- what other causes still need workup if blood and imaging disagree
You Might Also Like
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
